Literature DB >> 20857240

Cardiac assessment in duchenne and becker muscular dystrophies.

Anitra Romfh1, Elizabeth M McNally.   

Abstract

Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophies. In addition to muscle disease, there nearly always is an associated cardiomyopathy in Duchenne or Becker muscular dystrophy. In these muscular dystrophies, the severity of cardiomyopathy and congestive heart failure may not parallel the severity of skeletal muscle disease. Loss of normal dystrophin function in the heart produces four-chamber dilation and reduction in left ventricular function that develop after the onset of muscle weakness. Arrhythmias affecting both atrial and ventricular rhythms occur and may be life threatening. The degree to which hypoventilation and pulmonary dysfunction are present also directly affect cardiac function in muscular dystrophy. Care guidelines recently were issued to outline surveillance and treatment strategies for the younger patient with Duchenne muscular dystrophy. Herein, we review those guidelines, and additionally, provide recommendations for monitoring and treating cardiac disease in the populations of advanced Duchenne and Becker muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857240     DOI: 10.1007/s11897-010-0028-2

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  35 in total

1.  Cardioprotection for Duchenne's muscular dystrophy.

Authors:  Y Ishikawa; J R Bach; R Minami
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

2.  Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne's muscular dystrophy: relationship to clinical outcome.

Authors:  N Giatrakos; M Kinali; D Stephens; D Dawson; F Muntoni; P Nihoyannopoulos
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

3.  The American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation.

Authors:  David J Birnkrant
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

4.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy.

Authors:  Hitoko Ogata; Satoshi Nakatani; Yuka Ishikawa; Akifumi Negishi; Michiko Kobayashi; Yukitoshi Ishikawa; Ryoji Minami
Journal:  Int J Cardiol       Date:  2006-07-13       Impact factor: 4.164

6.  Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy.

Authors:  Ralf Bauer; Volker Straub; Alison Blain; Kate Bushby; Guy A MacGowan
Journal:  Eur J Heart Fail       Date:  2009-02-20       Impact factor: 15.534

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

8.  Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy.

Authors:  Marly Conceição Silva; Zilda Maria Alves Meira; Juliana Gurgel Giannetti; Marcelo Moreira da Silva; Alysson Félix Oliveira Campos; Márcia de Melo Barbosa; Geraldo Moll Starling Filho; Rogério de Aguiar Ferreira; Mayana Zatz; Carlos Eduardo Rochitte
Journal:  J Am Coll Cardiol       Date:  2007-04-23       Impact factor: 24.094

9.  Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.

Authors:  Hitoko Ogata; Yuka Ishikawa; Yukitoshi Ishikawa; Ryoji Minami
Journal:  J Cardiol       Date:  2008-10-23       Impact factor: 3.159

10.  Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy.

Authors:  Vincenzo Giglio; Vincenzo Pasceri; Loredana Messano; Fortunato Mangiola; Luciano Pasquini; Antonio Dello Russo; Antonello Damiani; Massimiliano Mirabella; Giuliana Galluzzi; Pietro Tonali; Enzo Ricci
Journal:  J Am Coll Cardiol       Date:  2003-07-16       Impact factor: 24.094

View more
  33 in total

1.  Focal but reversible diastolic sheet dysfunction reflects regional calcium mishandling in dystrophic mdx mouse hearts.

Authors:  Ya-Jian Cheng; Di Lang; Shelton D Caruthers; Igor R Efimov; Junjie Chen; Samuel A Wickline
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-07-09       Impact factor: 4.733

Review 2.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

Review 3.  Cardiomyopathy in becker muscular dystrophy: Overview.

Authors:  Rady Ho; My-Le Nguyen; Paul Mather
Journal:  World J Cardiol       Date:  2016-06-26

Review 4.  Treatment of dystrophin cardiomyopathies.

Authors:  Josef Finsterer; Linda Cripe
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

5.  Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation.

Authors:  Kinya Seo; Peter P Rainer; Dong-Ik Lee; Scarlett Hao; Djahida Bedja; Lutz Birnbaumer; Oscar H Cingolani; David A Kass
Journal:  Circ Res       Date:  2014-01-21       Impact factor: 17.367

6.  The correlation analysis of functional factors and age with duchenne muscular dystrophy.

Authors:  Il-Young Jung; Jong Hee Chae; Sue Kyung Park; Je Ho Kim; Jung Yoon Kim; Sang Joon Kim; Moon Suk Bang
Journal:  Ann Rehabil Med       Date:  2012-02-29

7.  Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.

Authors:  Kristine M Wadosky; Luge Li; Jessica E Rodríguez; Jin-Na Min; Dan Bogan; Jason Gonzalez; Cam Patterson; Joe N Kornegay; Monte Willis
Journal:  Muscle Nerve       Date:  2011-08-08       Impact factor: 3.217

8.  Beneficial effect of ivabradine in dilated cardiomyopathy from Becker muscular dystrophy.

Authors:  J Finsterer; C Stöllberger; E Berger
Journal:  Herz       Date:  2012-06-22       Impact factor: 1.443

9.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Nancy J Halnon; John T Kissel; Xin He; Tam Tran; Suzanne Smart; Beth McCarthy; Michael D Taylor; John L Jefferies; Jill A Rafael-Fortney; Jeovanna Lowe; Sharon L Roble; Linda H Cripe
Journal:  Lancet Neurol       Date:  2014-12-30       Impact factor: 44.182

10.  Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.

Authors:  Tatyana A Meyers; DeWayne Townsend
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.